Back to News
Market Impact: 0.5
Lilly’s Newest Bull Says Near 300% Rally Is Only the Beginning
Source: Bloomberg
Healthcare & BiotechCompany FundamentalsInvestor Sentiment & Positioning
Eli Lilly shares have risen about 300% since approval of its first GLP-1 medicine more than four years ago, lifting the company above a $1 trillion market capitalization. The gain makes Lilly the world's most valuable pharmaceutical company, underscoring the exceptional investor response to its GLP-1 franchise.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.80
Ticker Sentiment
LLY0.90
More News
- Why Twist Bioscience Stock Skyrocketed This Week
- Insilico Medicine’s Alex Zhavoronkov bets China and AI can deliver the drug industry’s next breakthrough
- U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
- Stocks face a key hurdle in next week’s U.S.-China summit. Here’s what’s at stake
- Warren Buffett stepping down as chairman of Berkshire Hathaway: 'Father Time always wins'
- Three words from Kevin Warsh have Wall Street wondering how far the Fed will go with rate hikes